Los Angeles Capital Management & Equity Research Inc. Has $634,000 Position in Natus Medical Inc. (BABY)
Los Angeles Capital Management & Equity Research Inc. lowered its position in shares of Natus Medical Inc. (NASDAQ:BABY) by 3.0% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,764 shares of the company’s stock after selling 525 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned 0.05% of Natus Medical worth $634,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of BABY. Norges Bank acquired a new position in shares of Natus Medical during the fourth quarter worth about $15,163,000. Apex Capital Management boosted its position in shares of Natus Medical by 19.5% in the first quarter. Apex Capital Management now owns 381,746 shares of the company’s stock worth $14,670,000 after buying an additional 62,350 shares in the last quarter. Aperio Group LLC boosted its position in shares of Natus Medical by 37.3% in the first quarter. Aperio Group LLC now owns 8,823 shares of the company’s stock worth $339,000 after buying an additional 2,398 shares in the last quarter. Pacad Investment Ltd. acquired a new position in shares of Natus Medical during the first quarter worth about $284,000. Finally, Motley Fool Asset Management LLC boosted its position in shares of Natus Medical by 67.0% in the first quarter. Motley Fool Asset Management LLC now owns 405,741 shares of the company’s stock worth $15,593,000 after buying an additional 162,841 shares in the last quarter. Hedge funds and other institutional investors own 87.92% of the company’s stock.
Natus Medical Inc. (NASDAQ:BABY) traded up 1.10% on Thursday, hitting $44.27. 215,566 shares of the company were exchanged. The stock has a market capitalization of $1.44 billion, a P/E ratio of 38.16 and a beta of 0.85. Natus Medical Inc. has a 52 week low of $29.54 and a 52 week high of $51.05. The company has a 50 day moving average price of $39.94 and a 200-day moving average price of $36.69.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.03. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The business earned $96 million during the quarter, compared to analyst estimates of $92.71 million. During the same period in the prior year, the business earned $0.34 EPS. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, equities analysts expect that Natus Medical Inc. will post $1.70 earnings per share for the current fiscal year.
BABY has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Thursday, July 7th. Raymond James Financial Inc. upgraded shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective for the company in a report on Tuesday, September 13th.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.